Facticin 320 mg Tab. 320mg

Tablet

Pack Size : 6 Strip x 1 Strip

Generics : Gemifloxacin

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 391.14

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Flogem 320 mg Tab Opsonin Pharma Ltd.

Tk 65.45

Tablet Gemitab 320 mg Tab Ibn Sina Pharmaceutical Ind. Ltd.

Tk 35.00

More Information About - Facticin 320 mg Tab. 320mg

Description

Generic Name

Gemifloxacin

Precaution

Patient w/ known or suspected CNS disorders (e.g. seizure disorders) or other risk factors predisposing to seizures, myasthenia gravis, previous tendon disorders (e.g. rheumatoid arthritis), history of QT interval prolongation, significant bradycardia or acute myocardial ischaemia, uncorrected electrolyte disorders. Kidney, heart or lung transplant recipients. Renal impairment. Pregnancy and lactation. Patient Counselling May impair ability to perform activities that require mental alertness or coordination (e.g. driving, operating machinery). Rest and refrain from doing strenuous physical activity as it may increase risk of tendon rupture. Avoid excessive exposure to sunlight or artificial UV light (e.g. tanning beds) and use protective measures (e.g. sunscreen, wear loose-fitting clothes) if staying outdoors is necessary during therapy. Monitoring Parameters Monitor WBC, signs and symptoms of infection and renal function. Lactation: excretion in milk unknown; do not use unless benefit to mother outweighs risk

Indication

Chronic bronchitis, Community-acquired pneumonia

Contra Indication

Hypersensitivity. Patients receiving class IA or III antiarrhythmics.

Dose

N/A

Side Effect

1-10% Diarrhea (5%),Headache (4%),Nausea (4%),Rash (4%),Transaminases increased (1-4%),Abdominal pain (2%),Dizziness (2%),Vomiting (2%),Neutropenia (1%),Platelets increased (1%),Thrombocythemia (1%),GGT increased (1%) <1% Peripheral neuropathy,Photosensitivity,Tendon rupture

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

The bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

Interaction

Additive effect on QT interval prolongation w/ class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmics and other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Renal clearance reduced w/ probenecid. Decreased absorption w/ Al or Mg-containing antacids, buffered didanosine, sucralfate or dietary supplements containing metal cations (e.g. Zn, Mg, Fe). Increased risk of severe tendon disorders esp in elderly (>60 yr) w/ corticosteroids. May increase prothrombin time, INR and/or bleeding w/ warfarin.

Pregnancy Category Note

Pregnancy Limited available human data with use in pregnant women are insufficient to inform an associated risk of miscarriages, major birth defects, and/or adverse maternal or fetal outcomes; based on animal studies with gemifloxacin, therapy, may cause fetal harm; in animal reproduction studies, administration of drug to pregnant mice and rabbits during the period of organogenesis produced embryofetal toxicity at exposures up to 2 and 3 times, respectively, the maximum recommended human dose; advise pregnant women of potential risk to fetus Lactation There is no data on presence of gemifloxacin in human milk, effects on milk production, on breastfed infant; drug is excreted in breast milk of rats; developmental and health benefits of breastfeeding should be considered along with mother?s clinical need for therapy and any potential adverse effects on breastfed child from treatment or from underlying maternal condition

Adult Dose

Oral Acute bacterial exacerbation of chronic bronchitis Adult: 320 mg once daily for 5 days. Community-acquired pneumonia Adult: Mild to moderate: 320 mg once daily for 7 days.

Child Dose

Safety and efficacy not established

Renal Dose

Renal impairment: CrCl (ml/min) <40 (or patient on haemodialysis/CAPD) 160 mg once daily.

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.